Home
Clinical Trials
NCT03424005

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

792 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-30

Study Completion Date

2030-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer.

The study will be performed in two stages. During Stage 1, six cohorts will be enrolled in parallel in this study:

Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort).

Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naïve cohort).

Cohort 3, 5, and 6 will consist of participants with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease with one or more PIK3CA mutations.

Cohort 4 will consist of participants with locally advanced or metastatic HER2+ /HER2-low disease with one or more PIK3CA mutations who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort).

In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). During Stage 2, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination, provided Stage 2 is open for enrollment and all eligibility criteria are met.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastatic Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Atezolizumab + Nab-Paclitaxel

1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus nab-paclitaxel until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Enrollment is closed.

Group Type ACTIVE_COMPARATOR

Atezolizumab

Intervention Type DRUG

For Atezolizumab + SGN-LIV1A, Atezolizumab + Sacituzumab Govitecan, or Atezolizumab + Chemo arms: atezolizumab will be administered intravenously (IV), 1200 mg, on Day 1 of each 21-day cycle.

For Atezolizumab + Nab-Paclitaxel, Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Ipatasertib, or Atezolizumab + Nab-Paclitaxel + Tocilizumab arms: atezolizumab will be administered IV, 840 mg on Days 1 and 15 of each 28-day cycle.

Nab-Paclitaxel

Intervention Type DRUG

Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.

Atezolizumab + Nab-Paclitaxel + Tocilizumab

1L PD-L1-positive participants will receive combination treatment with atezolizumab plus nab-paclitaxel and tocilizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Enrollment is closed.

Group Type EXPERIMENTAL

Atezolizumab

Intervention Type DRUG

Tocilizumab

Intervention Type DRUG

Tocilizumab will be administered IV, 8 mg/kg on Day 1 of each 28-day cycle.

Nab-Paclitaxel

Intervention Type DRUG

Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.

Atezolizumab + Sacituzumab Govitecan

1L PD-L1-positive participants will receive doublet combination treatment with atezolizumab plus sacituzumab govitecan until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Enrollment is closed.

Group Type EXPERIMENTAL

Atezolizumab

Intervention Type DRUG

Sacituzumab Govitecan

Intervention Type DRUG

Sacituzumab govitecan will be administered by IV infusion, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.

Capecitabine

2L CIT-naïve participants will receive capecitabine until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1).

Participants who progressed on treatment may have the option of receiving atezolizumab along with chemotherapy (chemo) during stage 2, provided they meet the eligibility criteria.

Enrollment is closed.

Group Type ACTIVE_COMPARATOR

Capecitabine

Intervention Type DRUG

Capecitabine will be administered 1250 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day cycle.

Atezolizumab + Ipatasertib

2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus ipatasertib until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.

Enrollment is closed and participant follow-up is complete.

Group Type EXPERIMENTAL

Atezolizumab

Intervention Type DRUG

Ipatasertib

Intervention Type DRUG

Ipatasertib will be administered by mouth 400 mg once a day, on Days 1-21 of each 28-day cycle.

Atezolizumab + SGN-LIV1A

2L CIT-naïve participants will receive doublet combination treatment with atezolizumab plus SGNLIV1A until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Patients who experience loss of clinical benefit as determined by the investigator or unacceptable toxicity related to SGN-LIV1A will be given the option of receiving Atezolizumab + chemo during Stage 2, provided they meet the eligibility criteria.

Enrollment is closed.

Group Type EXPERIMENTAL

Atezolizumab

Intervention Type DRUG

SGN-LIV1A

Intervention Type DRUG

SGN-LIV1A will be administered IV, 2.5 milligrams per kilogram (mg/kg) (maximum calculated dose 250 mg), on Day 1 of each 21-day cycle.

Atezolizumab + Selicrelumab + Bevacizumab

2L-CIT-naïve participants will receive doublet combination treatment with atezolizumab plus selicrelumab and bevacizumab until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Participants who progressed on treatment may have the option of receiving atezolizumab + chemo, provided they meet the eligibility criteria.

Enrollment is closed and participant follow-up is complete.

Group Type EXPERIMENTAL

Atezolizumab

Intervention Type DRUG

Bevacizumab

Intervention Type DRUG

Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28-day cycle.

Selicrelumab

Intervention Type DRUG

Selicrelumab will be administered by subcutaneous (SC) injection, at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (Cycle = 28 days).

Atezolizumab + Chemo (Gemcitabine + Carboplatin or Eribulin)

2L CIT-naïve participants enrolled in the active comparator arm who experience disease progression per RECIST v1.1 and 2L CIT-naïve participants enrolled in an experimental arm who experience loss of clinical benefit as determined by the investigator may receive doublet combination treatment with atezolizumab plus chemo (gemcitabine + carboplatin or eribulin) until unacceptable toxicity or loss of clinical benefit as determined by the investigator.

Enrollment is closed and participant follow-up is complete.

Group Type EXPERIMENTAL

Atezolizumab

Intervention Type DRUG

Chemotherapy (Gemcitabine + Carboplatin or Eribulin)

Intervention Type DRUG

Gemcitabine will be administered by IV, 1000 mg/m\^2, along with carboplatin, by IV, on Days 1 and 8 of each 21-day cycle.

Or

Eribulin will be administered IV, 1.4 mg/m\^2 on Days 1 and 8 of each 21-day cycle.

Inavolisib + Abemaciclib + Fulvestrant

HR+ participants will receive treatment with inavolisib plus abemaciclib plus fulvestrant until unacceptable toxicity or disease progression determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Abemaciclib

Intervention Type DRUG

Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle.

Fulvestrant

Intervention Type DRUG

For Inavolisib + Abemaciclib + Fulvestrant, Inavolisib + Ribociclib (Dose #1) + Fulvestrant, Inavolisib + Ribociclib (Dose #2) + Fulvestrant, or Inavolisib + Atirmociclib + Fulvestrant arms:

Fulvestrant 500 mg, administered as an IM injection on Days 1 and 15 of Cycle 1, followed by Day 1 of each 28-day cycle thereafter.

For Empa + Inavolisib + Fulvestrant ± Palbociclib, or Metformin + Inavolisib + Fulvestrant ± Palbociclib arms:

Fulvestrant 500 mg, administered as an IM injection on Day 1 and as per local prescribing guidelines thereafter.

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Inavolisib + Ribociclib (Dose #1) + Fulvestrant

HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Fulvestrant

Intervention Type DRUG

Ribociclib (Dose #1)

Intervention Type DRUG

Ribociclib tablets will be administered by mouth once daily.

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Inavolisib + Ribociclib (Dose #1) + Letrozole

HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Ribociclib (Dose #1)

Intervention Type DRUG

Ribociclib tablets will be administered by mouth once daily.

Letrozole

Intervention Type DRUG

Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle.

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Inavolisib + Ribociclib (Dose #2) + Fulvestrant

HR+ participants will receive treatment with inavolisib plus ribociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Fulvestrant

Intervention Type DRUG

Ribociclib (Dose #2)

Intervention Type DRUG

Ribociclib tablets will be administered by mouth once daily.

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Inavolisib + Ribociclib (Dose #2) + Letrozole

HR+ participants will receive treatment with inavolisib plus ribociclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Ribociclib (Dose #2)

Intervention Type DRUG

Ribociclib tablets will be administered by mouth once daily.

Letrozole

Intervention Type DRUG

Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle.

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Inavolisib + Abemaciclib + Letrozole

HR+ participants will receive treatment with inavolisib plus abemaciclib plus letrozole until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Abemaciclib

Intervention Type DRUG

Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle.

Letrozole

Intervention Type DRUG

Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle.

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Inavolisib (Dose #1) + Trastuzumab Deruxtecan

HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Inavolisib (Dose #1)

Intervention Type DRUG

Inavolisib tablets will be administered by mouth once daily.

Trastuzumab Deruxtecan

Intervention Type DRUG

Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle.

Inavolisib (Dose #2) + Trastuzumab Deruxtecan

HER2+/HER2-low participants will receive inavolisib + trastuzumab deruxtecan until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Trastuzumab Deruxtecan

Intervention Type DRUG

Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle.

Inavolisib (Dose #2)

Intervention Type DRUG

Inavolisib tablets will be administered by mouth once daily.

Empagliflozin (Empa) + Inavolisib (Inavo) + Fulvestrant (Fulv) ± Palbociclib (Palbo)

Participants with locally advanced or metastatic, HR+, HER2- participants will receive empagliflozin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Fulvestrant

Intervention Type DRUG

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Empagliflozin

Intervention Type DRUG

Empagliflozin, administered orally, once daily (QD)

Palbociclib

Intervention Type DRUG

For Empagliflozin + Inavolisib + Fulvestrant ± Palbociclib arm:

Palbociclib 125 mg administered orally, QD in Cycle 1 followed by 125 mg on Days 1-21 of each cycle.

For Metformin + Inavolisib + Fulvestrant ± Palbociclib arm: Palbociclib 125 mg administered orally, QD in Cycle 1, followed by 125 mg on Days 1-21 of each cycle (Cycle=28 days).

Metformin (Metf) + Inavolisib + Fulvestrant ± Palbociclib

Participants with locally advanced or metastatic, HR+, HER2- participants will receive metformin plus inavolisib plus fulvestrant with or without palbociclib until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Fulvestrant

Intervention Type DRUG

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Palbociclib

Intervention Type DRUG

Metformin

Intervention Type DRUG

Metf 1000 mg administered orally QD.

Inavolisib + Atirmociclib (Atirmo) + Fulvestrant

Participants will receive inavolisib plus atirmociclib plus fulvestrant until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

Group Type EXPERIMENTAL

Fulvestrant

Intervention Type DRUG

Inavolisib

Intervention Type DRUG

Inavolisib tablets will be administered by mouth OD.

Atirmociclib

Intervention Type DRUG

Atirmociclib administered orally, BID on Days 1-28 for each 28-day cycle.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Capecitabine

Capecitabine will be administered 1250 milligrams per square meter (mg/m\^2) orally twice daily on Days 1-14 of each 21-day cycle.

Intervention Type DRUG

Atezolizumab

Intervention Type DRUG

Ipatasertib

Ipatasertib will be administered by mouth 400 mg once a day, on Days 1-21 of each 28-day cycle.

Intervention Type DRUG

SGN-LIV1A

SGN-LIV1A will be administered IV, 2.5 milligrams per kilogram (mg/kg) (maximum calculated dose 250 mg), on Day 1 of each 21-day cycle.

Intervention Type DRUG

Bevacizumab

Bevacizumab will be administered IV, 10 mg/kg, on Days 1 and 15 of each 28-day cycle.

Intervention Type DRUG

Chemotherapy (Gemcitabine + Carboplatin or Eribulin)

Intervention Type DRUG

Selicrelumab

Selicrelumab will be administered by subcutaneous (SC) injection, at a fixed dose of 16 mg on Day 1 of Cycles 1 to 4 and every third cycle thereafter (Cycle = 28 days).

Intervention Type DRUG

Tocilizumab

Tocilizumab will be administered IV, 8 mg/kg on Day 1 of each 28-day cycle.

Intervention Type DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered IV, 100 mg/m\^2, on Days 1, 8, and 15 of each 28-day cycle.

Intervention Type DRUG

Sacituzumab Govitecan

Sacituzumab govitecan will be administered by IV infusion, 10 mg/kg, on Days 1 and 8 of each 21-day cycle.

Intervention Type DRUG

Abemaciclib

Abemaciclib tablets will be administered at a dose of 150 mg twice daily by mouth on Days 1-28 of each 28-day cycle.

Intervention Type DRUG

Fulvestrant

Intervention Type DRUG

Ribociclib (Dose #1)

Ribociclib tablets will be administered by mouth once daily.

Intervention Type DRUG

Inavolisib (Dose #1)

Inavolisib tablets will be administered by mouth once daily.

Intervention Type DRUG

Trastuzumab Deruxtecan

Trastuzumab Deruxtecan will be administered IV, 5.4 mg/kg on Day 1 of each 21-day cycle.

Intervention Type DRUG

Ribociclib (Dose #2)

Ribociclib tablets will be administered by mouth once daily.

Intervention Type DRUG

Letrozole

Letrozole tablets will be administered at a dose of 2.5 mg once a day by mouth on Days 1-28 of each 28-day cycle.

Intervention Type DRUG

Inavolisib (Dose #2)

Inavolisib tablets will be administered by mouth once daily.

Intervention Type DRUG

Inavolisib

Inavolisib tablets will be administered by mouth OD.

Intervention Type DRUG

Empagliflozin

Empagliflozin, administered orally, once daily (QD)

Intervention Type DRUG

Palbociclib

Intervention Type DRUG

Metformin

Metf 1000 mg administered orally QD.

Intervention Type DRUG

Atirmociclib

Atirmociclib administered orally, BID on Days 1-28 for each 28-day cycle.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RO0091978 RO5541267 RO7235441, Ladiratuzumab vedotin RO4877533 RO0247506 RO7445735 RO7071651 RO7072612 GDC-0077, RO7113755 RO7072612 GDC-0077, RO7113755 GDC-0077, RO7113755

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must meet all of the following criteria to qualify for Stage 1 (all cohorts) and to qualify for Stage 2 (2L CIT-naïve cohort):

* Age \>/= 18 years at the time of signing Informed Consent Form
* Eastern cooperative oncology group (ECOG) performance status of 0 or 1
* Able to comply with the study protocol, in the investigator's judgment
* Metastatic or inoperable locally advanced breast cancer
* Measurable disease (at least one target lesion) according to RECIST v1.1
* Life expectancy \>/= 3 months, as determined by the investigator
* Tumor accessible for biopsy, unless archival tissue is available
* Availability of a representative tumor specimen that is suitable for biomarker analysis via central testing
* Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from breastfeeding and donating eggs, as outlined for each specific treatment arm
* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm

Exclusion Criteria

* Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, CD40 agonists or interleukin-2 (IL-2) or IL-2-like compounds
* Biologic treatment (e.g., bevacizumab) within 2 weeks prior to initiation of study treatment, or other systemic treatment for TNBC within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
* Eligibility only for the control arm

* Adverse events from prior anti-cancer therapy that have not resolved to Grade \</= 1 or better with the exception of alopecia of any grade and Grade \</= 2 peripheral neuropathy
* Treatment with investigational therapy within 28 days prior to initiation of study treatment
* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
* Uncontrolled tumor-related pain
* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
* History of leptomeningeal disease
* Active or history of autoimmune disease or immune deficiency
* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
* Active tuberculosis
* Severe infection within 4 weeks prior to initiation of study treatment
* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
* Significant cardiovascular disease
* Prior allogeneic stem cell or solid organ transplantation
* History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
* Pregnancy or breastfeeding, or intention of becoming pregnant during the study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

City of Hope

Duarte, California, United States

Site Status COMPLETED

University of California San Diego Medical Center

La Jolla, California, United States

Site Status COMPLETED

Stanford Cancer Institute

Stanford, California, United States

Site Status WITHDRAWN

Rocky Mountain Cancer Center - Longmont

Longmont, Colorado, United States

Site Status COMPLETED

H. Lee Moffitt Cancer Center and Research Inst.

Tampa, Florida, United States

Site Status COMPLETED

Hackensack Univ Medical Center

Hackensack, New Jersey, United States

Site Status WITHDRAWN

Regional Cancer Care Associates, LLC

Howell Township, New Jersey, United States

Site Status WITHDRAWN

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Site Status WITHDRAWN

NYU Langone Medical Center

New York, New York, United States

Site Status WITHDRAWN

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, United States

Site Status WITHDRAWN

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status WITHDRAWN

Tennessee Oncology - Chattanooga Oncology & Hematology Associates

Chattanooga, Tennessee, United States

Site Status RECRUITING

The West Clinic

Germantown, Tennessee, United States

Site Status RECRUITING

Tennessee Oncology PLLC

Nashville, Tennessee, United States

Site Status RECRUITING

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status RECRUITING

Texas Oncology-Plano East

Plano, Texas, United States

Site Status WITHDRAWN

Peter MacCallum Cancer Centre-East Melbourne

Melbourne, Victoria, Australia

Site Status RECRUITING

Fiona Stanley Hospital - Medical Oncology

Murdoch, Western Australia, Australia

Site Status RECRUITING

Centre Léon Bérard

Lyon, , France

Site Status ACTIVE_NOT_RECRUITING

Institut régional du Cancer Montpellier

Montpellier, , France

Site Status WITHDRAWN

Institut Universitaire du Cancer de Toulouse-Oncopole

Toulouse, , France

Site Status RECRUITING

Gustave Roussy

Villejuif, , France

Site Status RECRUITING

Universitätsklinikum Erlangen

Erlangen, , Germany

Site Status RECRUITING

Universitätsklinikum Essen

Essen, , Germany

Site Status RECRUITING

Rambam Medical Center

Haifa, , Israel

Site Status RECRUITING

Shaare Zedek Medical Center

Jerusalem, , Israel

Site Status RECRUITING

Hadassah University Medical Center

Jerusalem, , Israel

Site Status RECRUITING

Rabin MC

Petah Tikva, , Israel

Site Status RECRUITING

Sheba Medical Center

Ramat Gan, , Israel

Site Status RECRUITING

Tel-Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status RECRUITING

Assuta Medical Centers

Tel Aviv, , Israel

Site Status RECRUITING

National Cancer Center Clinical Trials Center / Center for Breast Cancer

Goyang-si, , South Korea

Site Status RECRUITING

Seoul National University Hospital

Seoul, , South Korea

Site Status RECRUITING

Severance Hospital

Seoul, , South Korea

Site Status RECRUITING

University of Ulsan College of Medicine - Asan Medical Center

Seoul, , South Korea

Site Status RECRUITING

Samsung Medical Center

Seoul, , South Korea

Site Status RECRUITING

Hospital del Mar

Barcelona, , Spain

Site Status RECRUITING

Vall d?Hebron Institute of Oncology (VHIO), Barcelona

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario Ramon y Cajal

Madrid, , Spain

Site Status RECRUITING

Centro Integral Oncológico Clara Campal Ensayos Clínicos START

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status RECRUITING

National Cheng Kung University Hospital

Tainan, , Taiwan

Site Status RECRUITING

National Taiwan University Hospital

Taipei, , Taiwan

Site Status RECRUITING

Beatson West of Scotland Cancer Centre

Glasgow, , United Kingdom

Site Status COMPLETED

Barts Health NHS Trust - St Bartholomew's Hospital

London, , United Kingdom

Site Status COMPLETED

Countries

Review the countries where the study has at least one active or historical site.

United States Australia France Germany Israel South Korea Spain Taiwan United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Reference Study ID Number: CO40115 https://forpatients.roche.com/

Role: CONTACT

Phone: 888-662-6728 (U.S. and Canada)

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-002038-21

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

2023-503629-20-00

Identifier Type: CTIS

Identifier Source: secondary_id

CO40115

Identifier Type: -

Identifier Source: org_study_id